Erica Jackson
University of South Florida
5 Papers
27 Citations
Erica Jackson is an academic researcher from University of South Florida. The author has contributed to research in topics: Docetaxel & Immune system. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Hatem Soliman,Erica Jackson,Tony Neuger,Claire Dees,Donald R. Harvey,Hyo S. Han,Roohi Ismail-Khan,Susan Minton,Nicholas N. Vahanian,Charles J. Link,Daniel M. Sullivan,Scott J. Antonia +11 more
TL;DR: Docetaxel plus indoximod was well tolerated with no increase in expected toxicities or pharmacokinetic interactions and was active in a pretreated population of patients with metastatic solid tumors.
A phase I study of indoximod in combination with docetaxel in metastatic solid tumors.
Erica Jackson,Elizabeth Claire Dees,John S. Kauh,R. Donald Harvey,Anthony Neuger,Richard Lush,Scott J. Antonia,Susan Minton,Roohi Ismail-Khan,Hyo S. Han,Nicholas N. Vahanian,William Jay Ramsey,Charles J. Link,Howard Streicher,Daniel C. Sullivan,Hatem Soliman +15 more
TL;DR: A phase IB trial was designed to study the safety of the combination of docetaxel (Doc) and indoximod to determine the MTD for the combinationof Doc and oral indoxIMod.
21
A phase I study of 1-methyl-D-tryptophan in combination with docetaxel in metastatic solid tumors.
Erica Jackson,Susan Minton,Roohi Ismail-Khan,HS Han,Anthony Neuger,Scott J. Antonia,Daniel C. Sullivan,Hatem Soliman +7 more
TL;DR: A phase I trial was initiated to study the synergism and toxicity of 1-MT with docetaxel and the primary goal of this trial is to determine the MTD and toxicity for the combination of docetAXel and oral 1- MT.
5
Realizing the promise of breast cancer vaccines
Erica Jackson,Hatem Soliman +1 more
- 22 Aug 2012
TL;DR: A review of the literature was conducted to assess the use of vaccines in targeting transformed cells, and four vaccines currently under study were discussed, each summarizing the different vaccine platforms used to introduce target antigen to the patient's immune system.
Immunostimulators and Immunomodulators in Cancer Treatment
Brianna Oliver,Erica Jackson,Hatem Soliman +2 more
- 01 Jan 2015
TL;DR: This chapter gives an overview of some of the various agents in use, what type of adaptive immune response is more beneficial in cancer immunotherapy, and a promising way to classify the immunogenicity of tumors for treatment selection.